alexa Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary

Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy

Akihiko Osaki*

Department of Breast Oncology, Saitama Medical University International Medical Center, Japan

*Corresponding Author:
Akihiko Osaki
Department of Breast Oncology
Saitama Medical University International Medical Center, Japan
Tel: 81 42 984 4670
E-mail: [email protected]

Received Date: January 05, 2016; Accepted Date: February 15, 2016; Published Date: February 19, 2016

Citation: Akihiko Osaki (2016) Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. Chemo Open Access 5:187. doi: 10.4172/2167-7700.1000187

Copyright: © 2016 Osaki A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Additional therapy following definitive breast surgery after primary systemic chemotherapy (PSC) has not been correctly evaluated. Two unsolved problems regarding additional chemotherapy following PSC in advanced breast cancer are the subjects of this article. First is the prognostic impact of additional chemotherapy after surgery in patients with residual disease after completion of standard PSC, and second is the use of oral anticancer drugs such as S-1, which are known as metronomic chemotherapy, in this setting. Although there are many ongoing trials for breast cancer patients with residual disease after PSC in various subtypes, survival benefit has not been validated in clinical trials. Orally effective anticancer drugs such as S-1 and capecitabine can be further candidates for additional postoperative chemotherapy after PSC. Further studies are needed to evaluate the usefulness of these metronomic chemotherapies in this setting.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]icsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords